While all herpesviruses can switch between lytic and latent life cycle, which are both driven by specific transcription programs, a unique feature of latent EBV infection is the expression of several distinct and well-defined viral latent transcription programs called latency I, II, and III. Growth transformation of B-cells by EBV in vitro is based on the concerted action of Epstein-Barr virus nuclear antigens (EBNAs) and latent membrane proteins(LMPs). EBV growth-transformed B-cells express a viral transcriptional program, termed latency III, which is characterized by the coexpression of EBNA2 and EBNA-LP with EBNA1, EBNA3A, -3B, and -3C as well as LMP1, LMP2A, and LMP2B. The focus of this review will be to discuss the current understanding of how two of these proteins, EBNA2 and EBNA-LP, contribute to EBV-mediated B-cell growth transformation.
CITATION STYLE
Kempkes, B., & Ling, P. D. (2015). EBNA2 and its coactivator EBNA-LP. In Current Topics in Microbiology and Immunology (Vol. 391, pp. 35–59). Springer Verlag. https://doi.org/10.1007/978-3-319-22834-1_2
Mendeley helps you to discover research relevant for your work.